Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01350 (gastrin)
 9,683 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The mechanisms underlying the insulinotropic action of gastrin releasing peptide (GRP) were examined in normal mouse islets. GRP (100 nM) enhanced insulin secretion at glucose concentrations of > or = 11.1 mM (p < 0.05) but only in the presence of extracellular Ca2+. The insulinotropic effect of the peptide studied during perifusion at 16.7 mM glucose was transient and vanished in time. GRP stimulated, transiently, 45Ca2+ efflux from 45Ca(2+)-prelabeled islets, both in the presence and in the absence of extracellular Ca2+ (p < 0.05), suggesting that GRP releases Ca2+ from intracellular stores. Similarly, GRP increased 86Rb+ efflux from 86Rb(+)-prelabeled islets both in the presence and in the absence of extracellular Ca2+ (p < 0.001). In contrast to GRP-induced insulin secretion, the GRP-induced 86Rb+ efflux was sustained throughout the stimulation period, suggesting that increased K+ conductance may be involved in the vanishing effect of GRP on insulin secretion. Furthermore, both inhibition of protein kinase C (PKC) by staurosporine (1-10 microM) and down-regulation of PKC activity by long-term incubation with the phorbol ester 12-O-tetradecanoyl phorbol-13-acetate inhibited GRP-stimulated insulin secretion (p < 0.05). These results indicate that GRP activates PKC by an action involving liberation of Ca2+ from Ca2+ stores. Therefore, also the influence of GRP on phosphoinositide hydrolysis was studied by means of 3H efflux from myo-[2-3H]inositol prelabeled islets. However, GRP did not stimulate the 3H efflux. In contrast, GRP-stimulated insulin secretion was abolished by an inhibitor of phospholipase D, wortmannin (1 microM). The results suggest that GRP transiently potentiates glucose-induced insulin secretion by an action mediated by PKC activated by diacylglycerol formed through activation of phospholipase D. Simultaneously, an as yet unknown mechanism liberating Ca2+ from intracellular stores is activated.
 ...
PMID:Studies on the mechanisms by which gastrin releasing peptide potentiates glucose-induced insulin secretion from mouse islets. 892 19

The intracellular events involved in normal pancreatic growth have been extensively investigated in response to cholecystokinin. Recent data indicate that tyrosine kinase, phospholipase D, phosphatidylinositol 3-kinase, and p42/p44 MAPK are stimulated in rat pancreatic acinar cells. Although we begin to understand the intracellular signaling pathways activated in normal pancreas, such information is not yet available in pancreatic cancer cells. This study was undertaken to identify the growth factors and hormones involved in cell proliferation of two human pancreatic cancer cell lines of ductal origin, the MIA PaCa-2, and PANC-1 cells, and to establish the intracellular events involved in the control of their growth. We demonstrated that FGF-2, IGF-1, cerulein, and gastrin but not FGF-1, HGF, secretin, and PACAP, stimulated proliferation of MIA PaCa-2 and PANC-1 cells. Autocrine factors such as gastrin and IGF-1 were also responsible for their proliferation. In response to EGF, FGF-2, IGF-1, cerulein, gastrin and bombesin, tyrosine kinase, and tyrosine phosphatase activities were stimulated in both cell lines. The close relationship established between cell growth and tyrosine kinase activation results from the observation that maximal growth stimulation paralleled with maximal enzyme activation and that genistein, the tyrosine kinase inhibitor, blocked cell growth and enzyme activation. The implication of PLD in growth-stimulated processes is doubtful since all growth factors and hormones tested failed to stimulate an already very active PLD activity. We finally observed a constitutive activity of p44 MAPK in both cell lines and of p42 in MIA PaCa-2 cells. However, p38 and p42 were stimulated in MIA PaCa-2 and PANC-1 cells, respectively, by all growth factors and hormones.
 ...
PMID:Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. 986 51